1. In Vivo
  2. >>Deal-Making

J.P. Morgan 2024: Financial Forecast Is Sunny For Firms Poised For Pharma Deals

Clouds Seemed To Lift At Annual Industry Meeting

 
• By Mandy Jackson

Drug developers weathered a tough 2023, but the year ended with new clarity about interest rates and big pharma M&A priorities, reducing the risk of financial storms in 2024, investors and advisors said.

Sweeping view of a partly cloudy sunrise over the Ventura coastline
A new, sunnier day may be dawning in biopharma finance • Source: Shutterstock

The mood of biopharmaceutical company executives and investors attending this year’s J.P. Morgan Healthcare Conference in San Francisco was decidedly sunnier than in 2023 – and with good reason. Public company valuations spiked at the end of last year based on the prospect of stabilizing or declining interest rates in 2024 and a recent uptick in $1bn-plus merger and acquisition activity.

In terms of M&A, investors couldn’t be happier. Big pharma is back to buying small and mid-sized biopharma companies to refill their research and development pipelines and their commercial portfolios

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.